IgGenix
IgGenix is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases, empowering people to live life without the constant fear of a life-threatening allergic reaction. The company leverages its proprietary SEQ SIFTER single-cell RNA-sequencing-based discovery platform to capture extremely rare human B cells that produce IgE antibodies directly from…
Funding snapshot
About
IgGenix is a clinical-stage antibody discovery and development company with a mission to solve allergies and other immunological diseases, empowering people to live life without the constant fear of a life-threatening allergic reaction. The company leverages its proprietary SEQ SIFTER single-cell RNA-sequencing-based discovery platform to capture extremely rare human B cells that produce IgE antibodies directly from patient blood, then isolates and re-engineers fully human, high-affinity, allergen-specific IgG antibodies designed to block and prevent the allergic cascade. By targeting common immunodominant antigens and their most immunodominant epitopes across patients, IgGenix intends to treat both pediatric and adult populations. The company lead candidate IGNX001 is a first-in-class injectable, allergen-specific therapeutic for peanut allergy, currently in a Phase 1 clinical trial called ACCELERATE Peanut, which has completed enrollment and dosing. The clinical pipeline includes multiple food allergy programs targeting peanut (94% through Phase 1), a second allergy program (50% through IND-enabling), a third allergy program (25% through lead selection), and an atopic dermatitis program (12% through discovery). IgGenix is also conducting Institutional Review Board-approved observational studies across the United States, with research spanning food allergies including alpha-gal syndrome, egg, fish, milk, peanut, sesame, shellfish, soy, tree nuts, and wheat, as well as environmental allergies including cat, dog, dust, mold, and pollen. Founded in 2019 and headquartered in South San Francisco, California, IgGenix has raised approximately $75 million in Series B funding from investors including Alexandria, Lilly, Khosla Ventures, AllerFund, ShangBay Capital, Global Brain, and SBI Investment. Scientific co-founders include Stephen Quake from Stanford University and Kari Nadeau from Harvard School of Public Health.
Business model
Immunology > Drugs > Allergies,
Toxicology > Drugs,
Genomics > Applied Genomics > Clinical Genomics > Therapeutics
Team background
College Wise > Stanford University
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.